In:
Pediatric Blood & Cancer, Wiley, Vol. 69, No. 4 ( 2022-04)
Abstract:
Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m 2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively.
Type of Medium:
Online Resource
ISSN:
1545-5009
,
1545-5017
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2130978-4
Permalink